A year after donating stem cells to an Australian boy, Kam Saundh urges others to sign up.
Get the latest international news and world events from around the world.
The Startup Freezing Humans For Tomorrow — Interview with Dr Emil Kendziorra, CEO of Tomorrow.bio
Join us for a deep-dive conversation with Dr Emil Kendziorra, CEO of Tomorrow.bio, as we explore the cutting edge of cryopreservation and medical biostasis.
Dr Kendziorra, who began his career in cancer research with a summa cum laude degree from the University of Göttingen, shares his remarkable journey from academic science to entrepreneurship, and ultimately to founding Tomorrow.bio — a company he considers his life’s work.
In this interview, he discusses the motivations behind his pivot from traditional longevity research to the frontier of cryomedicine, the operational and emotional lessons learned from cryopreserving over 20 human patients and 10 pets, and his vision for making this technology more accessible in the future.
Tomorrow.bio stands as Europe’s fastest-growing cryopreservation company, with over 800 members across 200+ cities and 45+ countries. The company offers both whole-body cryopreservation and brain-only preservation, using a transparent pricing model designed for long-term value.
With a recent €5 million Seed round and a mission to advance medical biostasis, Emil discusses the unique challenges and opportunities of operating in this space, the ethical considerations of a technology that may not achieve revival for decades, and his long-term vision for the field.
Key Points.
A man with terminal glioblastoma was given 12–15 months to live
After four injections of a therapy called Anktiva, his latest scan came back normal.
The treatment has been studied for more than a decade and has shown promise across multiple cancer types, yet it’s only approved for a narrow form of bladder cancer.
Should potentially life-saving treatments move through the approval process faster for patients with no other options?
Age-Related ‘Unraveling’ of DNA May Be Reversible, Study Suggests
The slow march of time is inexorable and irreversible, but that doesn’t mean its effects on our bodies have to be etched in stone.
One of the more intriguing ideas in aging research is that growing old isn’t just a matter of damage accumulating over the years.
It may also be a story of lost information – the gradual breakdown of the molecular instructions that tell cells which genes to use and which to keep quiet.
Multifold increase in spinal inhibitory cell types with emergence of limb movement
Frog metamorphosis reveals how spinal circuits adapt to new motor demands. Vijatovic et al. demonstrate that the shift from tail-to limb-based locomotion coincides with expansion and diversification of V1 inhibitory neurons. Cross-species comparisons identify a conserved blueprint of tail and limb locomotion, with Engrailed-1 a global regulator of movement frequency.
